Adjuvant Antibody Therapy with Trastuzumab in Early Breast Cancer

Publisher： Karger

E-ISSN： 1661-3805|1|4|252-255

ISSN： 1661-3791

Source： Breast Care, Vol.1, Iss.4, 2006-09, pp. : 252-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

Current Status of Financing and Reimbursement of Trastuzumab (Herceptin®) for Adjuvant and Advanced Therapy of Breast Cancer in Germany

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 86-94

Karger

Access to resources Recommend Favorite

Advances in Adjuvant and Primary Systemic Therapy of Early Breast Cancer

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 129-133

Karger

Access to resources Recommend Favorite

Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 138-144

Karger

Access to resources Recommend Favorite

Trastuzumab for Early Breast Cancer: Hope or Hype?

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 66-67

Karger

Access to resources Recommend Favorite